Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 16/20 | 0.60 |
| ▸ | DRD2 | P14416 | 1/20 | 0.53 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.50 |
| ▸ | BCHE | P06276 | 1/20 | 0.49 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1570643 | 0.93 | HTR6 (0.58) | HTR6DRD2SCN9A | |
| SCHEMBL5705111 | 0.89 | SCN9A (0.52) | HTR6SCN9AGPR119 | |
| SCHEMBL25032332 | 0.86 | HTR6 (0.48) | HTR6DRD2SCN9ABCHETGFBR1 | |
| SCHEMBL31270546 | 0.86 | HTR6 (0.48) | HTR6DRD2SCN9ABCHETGFBR1 | |
| SCHEMBL558066 | 0.82 | SCN9A (0.61) | SCN9AGPR119MEN1KMT2A | |
| SCHEMBL27322905 | 0.81 | SCN9A (0.50) | SCN9AGPR119MEN1KMT2A | |
| SCHEMBL29212415 | 0.81 | HTR6 (0.47) | HTR6SCN9ABCHETGFBR1GPR119 | |
| SCHEMBL7482774 | 0.80 | HTR6 (0.71) | HTR6DRD2 | |
| SCHEMBL5203683 | 0.78 | HTR6 (0.51) | HTR6BCHETGFBR1GPR119 | |
| SCHEMBL14406151 | 0.78 | GPR119 (0.47) | HTR6SCN9AGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1691807-A1 | INDOLE DERIVATIVES FOR THE TREATMENT OF BONE DISEASES | Astellas Pharma Inc. (JP) | 2006-08-23 | — | — | EP | disclosed |
| US-20050245540-A1 | New methods | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| WO-2005056012-A1 | INDOLE DERIVATIVES FOR THE TREATMENT OF BONE DISEASES | ASTELLAS PHARMA INC. (JP) | 2005-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245540-A1 | New methods | TGFB1, TGFBR1, TGFB2 | HTR6 1013/4885DRD2 2595/4885SCN9A 2148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.